{'52WeekChange': None,
 'SandP52WeekChange': None,
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 28.85,
 'askSize': 1000,
 'averageDailyVolume10Day': 12462,
 'averageVolume': 17873,
 'averageVolume10days': 12462,
 'beta': None,
 'beta3Year': 1.17,
 'bid': 25.98,
 'bidSize': 1100,
 'bookValue': None,
 'category': 'Health',
 'circulatingSupply': None,
 'companyOfficers': [],
 'currency': 'USD',
 'dayHigh': 26.51,
 'dayLow': 25.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': None,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 26.868572,
 'fiftyTwoWeekHigh': 28.55,
 'fiftyTwoWeekLow': 12,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fundFamily': 'Loncar Investments',
 'fundInceptionDate': 1444694400,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': None,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': 'Exchange Traded Fund',
 'logo_url': '',
 'longBusinessSummary': 'The investment seeks to track the total return '
                        'performance, before fees and expenses, of the Loncar '
                        'Cancer Immunotherapy Index.\n'
                        ' The index is composed of the common stock of '
                        'approximately 25 pharmaceutical or biotechnology '
                        'companies identified by the fund&#39;s index '
                        'provider, as having a high strategic focus on the '
                        'development of drugs that harness the body&#39;s own '
                        'immune system to fight cancer. The adviser attempts '
                        'to invest all, or substantially all, of its assets in '
                        'the component securities and ADRs that make up the '
                        'index. Normally it will invest at least 80% of its '
                        'total assets in the component securities of the '
                        'index. The fund is non-diversified.',
 'longName': 'Loncar Cancer Immunotherapy ETF',
 'market': 'us_market',
 'marketCap': None,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_308386604',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': None,
 'navPrice': 27.09,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': None,
 'open': 26.51,
 'openInterest': None,
 'payoutRatio': None,
 'pegRatio': None,
 'phone': '800-617-0004',
 'previousClose': 26.7,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': None,
 'quoteType': 'ETF',
 'regularMarketDayHigh': 26.51,
 'regularMarketDayLow': 25.9,
 'regularMarketOpen': 26.51,
 'regularMarketPreviousClose': 26.7,
 'regularMarketPrice': 26.51,
 'regularMarketVolume': 37547,
 'revenueQuarterlyGrowth': None,
 'shortName': 'Loncar Cancer Immunotherapy ETF',
 'startDate': None,
 'strikePrice': None,
 'symbol': 'CNCR',
 'threeYearAverageReturn': 0.0558,
 'totalAssets': 43478008,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 23.573711,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '4f436133-24fa-3b1f-bff4-43d556ecff32',
 'volume': 37547,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'yield': 0,
 'ytdReturn': None}